Travere Therapeutics is entering a new chapter as CEO Eric Dube, Ph.D., prepares to step down following nearly eight years of leadership at the rare disease biotech. During his tenure, Dube helped transform the organization, including its evolution from Retrophin to Travere Therapeutics and the development and commercialization of Filspari for rare kidney diseases.
Bradley Campbell, former CEO of Amicus Therapeutics, is set to become Travere’s next CEO on December 1, 2026. His extensive experience in rare disease and biopharmaceutical leadership illustrates the specialized expertise often required to lead companies operating in complex and highly competitive markets.
For biotech and pharmaceutical companies, leadership transitions can have significant implications for organizational strategy, growth and long-term success. Identifying executives with the right combination of industry expertise, leadership experience and strategic vision is particularly important in areas such as rare disease, biotechnology and pharmaceutical development.
At The Bandish Group, we specialize in pharma executive search, biotech leadership recruiting, rare disease recruiting and life sciences executive recruitment. Our experienced recruiters understand the specialized talent landscape across pharmaceutical, biotechnology, medical device, diagnostics and digital healthcare organizations. We look beyond titles and keywords to identify executives who align with an organization’s goals, culture and long-term needs.
Finding the right life sciences leader isn’t simply about filling a position. It’s about finding the right fit for what’s next.
Click here to read the entire article.
